Treatments

*August 2021* Attention All Resisters! A new clinical trial finder, Medifind, is now live, which may help EGFR Resisters to quickly narrow down the many thousands of clinical trials based on information specific to us. This version includes the specific terms and keywords we would use to find an appropriate trial. So hopefully…

*June 2021* Treatment advances for patients with non–small cell lung cancer (NSCLC) who harbor HER2, EGFR, KRAS, and MET mutations have generated significant excitement and set the stage for further research aimed at generating better tolerated, more effective, and optimally sequenced treatments. Nicholas C. Rohs, MD, an assistant professor of medicine, hematology, and medical oncology at…

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation tyrosine kinase inhibitor, in both treatment-naïve and osimertinib (osi)-relapsed patients (pts) with EGFRm NSCLC (Cho Ann Oncol 2020;31:S813). We present updated results of the combination in osi-relapsed pts, including an…

*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung cancer (NSCLC) were first pinpointed in 2004. These mighty mutations have emerged as the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI) therapies, with deletions in exon 19 and the point…

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. Au has been approved in China for treatment of patients (pts)…

*June 2021* Note: The CHRYSALIS Trial, involves a combination of amivantamab and lazertinib in patients with Tagrisso-relapsed and chemo naïve cancer. Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the updated results of the…

*April 2021* Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated patients. Dr. Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors. Watch…

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed in combination with osimertinib. This builds on the limited data evaluating…

This is a great resource for newly-diagnosed EGFR lung cancer patients to learn from experts in this field about the disease and treatments available. Read more.

*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered and improved the therapeutic landscape of non-small cell lung cancer (NSCLC). ICIs confer a durable response in a subset of patients; however, their therapeutic role in oncogene-driven NSCLC remains unclear,…